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Background: Tuberous sclerosis complex (TSC) is a rare, multisystem, genetic disorder with an estimated
prevalence between 1/6800 and 1/15000. Although recent years have seen huge progress in understanding the
pathophysiology and in the management of TSC, several questions remain unanswered. A disease registry could be
an effective tool to gain more insights into TSC and thus help in the development of improved management
strategies.
Methods: TuberOus SClerosis registry to increase disease Awareness (TOSCA) is a multicentre, international disease
registry to assess manifestations, interventions, and outcomes in patients with TSC. Patients of any age diagnosed
with TSC, having a documented visit for TSC within the preceding 12 months, or newly diagnosed individuals are
eligible. Objectives include mapping the course of TSC manifestations and their effects on prognosis, identifying
patients with rare symptoms and co-morbidities, recording interventions and their outcomes, contributing to
creation of an evidence-base for disease assessment and therapy, informing further research on TSC, and evaluating
the quality of life of patients with TSC. The registry includes a ‘core’ section and subsections or ‘petals’. The ‘core’
section is designed to record general information on patients’ background collected at baseline and updated
annually. Subsections will be developed over time to record additional data related to specific disease manifestations
and will be updated annually. The registry aimed to enrol approximately 2000 patients from about 250 sites in 31
countries. The initial enrolment period was of 24 months. A follow-up observation period of up to 5 years is planned.
Results: A pre-planned administrative analysis of ‘core’ data from the first 100 patients was performed to evaluate the
feasibility of the registry. Results showed a high degree of accuracy of the data collection procedure. Annual interim
analyses are scheduled. Results of first interim analysis will be presented subsequent to data availability in 2014.
Implications: The results of TOSCA will assist in filling the gaps in understanding the natural history of TSC and help in
planning better management and surveillance strategies. This large-scale international registry to study TSC could serve
as a model to encourage planning of similar registries for other rare diseases.
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Tuberous sclerosis complex (TSC) is an autosomal dom-
inant genetic disorder resulting from mutations in either
TSC1 (encoding hamartin) or TSC2 (encoding tuberin)
[1]. The disease has an estimated prevalence between
1/6800 and 1/15000 population [2-4]. Tuberous sclerosis
complex can have a serious debilitating effect in affected
individuals. The disease is characterised by growth of
hamartomas in several organs, including the brain, kid-
neys, lungs, heart, eyes, and skin [1,4]. Tuberous scler-
osis complex can affect people of all age groups with
various organ systems involved in different ways and at
varying times. The manifestations appear to have an age-
related expression pattern; some manifestations are typ-
ically identifiable at birth while others develop later at
different ages. Some patients may have a mild form and
remain undiagnosed, whereas others may have a severe
disease. Moreover, the clinical presentation of TSC may
vary greatly even within a family [1,5,6].
The central nervous system is one of the most com-
monly and severely affected organ systems in patients
with TSC. Epilepsy is seen in 70% to 90% of patients,
usually begins in the first year of life, and is often refrac-
tory to treatment [7,8]. Autism spectrum disorder, intel-
lectual disability, and other neurodevelopmental and
psychiatric disorders associated with TSC also lead to a
significant disability [9]. The main structural brain
lesions include cortical tubers, subependymal nodules,
and subependymal giant cell astrocytomas (SEGAs)
[1,5]. Cortical tubers develop prenatally and are seen in
90% of patients. Subependymal nodules are seen in 80%
of patients but are usually asymptomatic [10]. SEGAs
are slow growing tumours seen in 10% to 15% of
patients, usually manifesting in the first two decades of
life [1,7]. Initially, SEGAs are asymptomatic but can
grow to a considerable size and cause ventricular dilata-
tion and hydrocephalus [8,10,11]. Renal angiomyolipo-
mas are seen in up to 80% of patients [7]. These usually
do not appear before 3 years of age [5]. Renal complica-
tions have been found to be the most frequent cause of
TSC-related mortality in adult patients [12]. Pulmonary
manifestation of TSC includes lymphangioleiomyoma-
tosis (LAM) which is seen in about 40% of women of
reproductive age [13]. Recently, a higher prevalence
(60% to 80%) of LAM in women over 30 years of age
has been reported [14]. Although symptomatic LAM is
less common, it has the potential to cause severe morbid-
ity, including pneumothorax, chylothorax, and respiratory
failure and can seriously influence the prognosis and
quality of life (QOL) [13-15]. Cutaneous manifestations
include angiofibromas, hypomelanotic macules, sha-
green patch, and ungual fibromas with each appearing
at a distinct age. Hypomelanotic macules are typically
detected in infancy or early childhood and shagreenpatch is more common after 5 years of age. Facial angiofi-
bromas usually appear in early childhood and progress in
late childhood or adolescence. These can cause disfigure-
ment and are, therefore, a cause of cosmetic and psycho-
logical concern [6,16]. Cardiac rhabdomyomas are present
in up to 70% of infants with TSC and can be detected in
prenatal ultrasound. Most do not cause clinical manifesta-
tions and regress spontaneously during the first few years
of life [16,17]. Similarly, ophthalmic lesions including retinal
hamartomas rarely interfere with vision [1]. In addition,
lesions can occur virtually in any other organ system.
Given that symptoms are varied and none can be consid-
ered pathognomonic, making an accurate diagnosis of TSC
can be a significant challenge. Specific criteria for the diag-
nosis of TSC have evolved over the years, as new genetic
and clinical information has become available. The diagnos-
tic criteria for TSC were first proposed in 1979 and there-
after, were revised in 1992 and 1998 [18-20]. In 2012, these
guidelines were further refined at the Second International
TSC Consensus Conference [21]. The panel also provided
the updated surveillance and management recommenda-
tions for standardised, optimal clinical management of
patients with TSC [22]. Two major changes in the most
recent diagnostic criteria were the reduction of diagnostic
classes from three (definite, probable, and possible) to two
(definite and possible) and the inclusion of positive genetic
testing as an independent diagnostic criterion. The identifi-
cation of either TSC1 or TSC2 pathogenic mutation is now
sufficient to make a definite diagnosis of TSC [21].
The discovery of the TSC genes helped in understanding
the pathogenesis of TSC. Mutations in either of the two
TSC genes are detected in approximately 85% of the pa-
tients. TSC1 and TSC2 play an important role in the nor-
mal functioning of the mammalian target of rapamycin
(mTOR) pathway. The proteins encoded by these two
genes form a tumour-suppressor complex, which regulates
activation of the mTOR complex 1. Mutations on either
of the two genes result in constitutive activation of the
mTOR pathway, which in turn leads to abnormal cellular
proliferation and differentiation producing the hamarto-
matous lesions [23]. mTOR inhibition as a treatment
approach for TSC has been investigated with promising
results. Everolimus, a potent, selective, orally bioavailable
mTOR inhibitor, has been approved for the treatment of
SEGA and renal angiomyolipoma associated with TSC
[24-29]. In addition, mTOR inhibitors also appear to have
a clinically beneficial effect on several other manifestations
of TSC including angiofibromas, LAM, and, potentially,
epilepsy [30-35].
Although numerous advances have been made in the
past decade to understand TSC, many gaps still remain.
The natural history of many of the manifestations, their
variability and their prognostic roles are not yet completely
understood. Although various manifestations appear to
Figure 1 TOSCA registry design.
Figure 2 The ‘flower and petal’ model of TOSCA registry.
Abbreviations: SEGA: Subependymal giant cell astrocytoma; TAND,
TSC-associated neuropsychiatric disorders; TSC: Tuberous
sclerosis complex.
Kingswood et al. Orphanet Journal of Rare Diseases 2014, 9:182 Page 3 of 9
http://www.ojrd.com/content/9/1/182have an age-related expression pattern, the published data
on detailed and long-term longitudinal description of
disease manifestations and their changes over time are
limited. Gaps also exist in understanding the following
aspects: rare symptoms and co-morbidities of TSC; the
relationship between genotype and phenotype; and the
various interventions, treatments, and their outcomes.
Further, long-term data for new intervention strategies
(e.g., mTOR inhibitors) are needed. We know that TSC
associated with a TSC2 gene mutation is typically more
severe than that caused by a TSC1 gene mutation. How-
ever, the reason for this is not clear [36]. The molecular
mechanism of TSC in 15% of patients with ‘no mutation
identified’ is also not yet known [5].
Making an accurate diagnosis and recommending
appropriate treatment and surveillance plan continue to
be challenging for the treating physician. Although revised
monitoring guidelines have been published recently, the
TSC consensus panel acknowledged that recommenda-
tions for many interventions and management strategies
were not based on a high level of evidence [22]. More
information on this rare disease is required to further
optimise management strategies. In 2011, Novartis in
collaboration with medical experts and patient advocates
evaluated the need for a TSC registry to address some of the
existing gaps. Online surveys were conducted in January
2011 and February 2011, by sending questionnaires to a
number of individuals and organisations in Europe that were
involved in management of TSC. All the complete responses
were analysed. The results from the survey and from round
table discussions suggested that national TSC registries did
not exist in many European countries. A need for collabor-
ation on a larger scale, instead of solely relying on the
evidence obtained from a limited number of patients was
strongly felt. There was a clear consensus regarding the need
to establish a registry, which resulted in the conception of
TuberOus SClerosis registry to increase disease Awareness
(TOSCA). Subsequently, some non-European countries also
joined the registry, thereby making TOSCA a truly global
venture. The data from this registry will assist in gaining a
better understanding of the clinical course of TSC, and thus,
provide substantial evidence on the appropriate clinical
surveillance of this disease with age-dependent mani-
festations. In this manuscript, we present the design
and methodology of TOSCA, which, to our knowledge,
is the first multi-country registry aimed at collecting
information on TSC.
Methods
Description of TOSCA registry design
TOSCA is a multicentre, international disease registry that
has been designed to collect data to assess the manifesta-
tions, interventions and their outcomes in patients with
TSC (Figure 1). The registry is structured retrospectivelyand prospectively to collect patient and disease infor-
mation. TOSCA consists of the main ‘core’ section and
subsections (also referred to as ‘petals’) (Figure 2). The
‘core’ section of the registry is designed to collect a gen-
eral predefined set of patient background data including
demographics, family history, prenatal history, and dis-
ease features (i.e., neurological, neuropsychiatric, renal,
cardiovascular, pulmonary). This mandatory section will
ensure that at least a minimum amount of essential
information on each patient is collected to allow mean-
ingful analyses. Additional and more detailed data
related to specific disease manifestations will be col-
lected in subsections of the registry. All participants
will have ‘core’ baseline data. In addition, an annual up-
date is required for the ‘core’ section and for subsection
data, as appropriate. In order to enhance active patient
partnership in this registry, a patient self-report section is
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tion including data on patient experience and QOL.
The data are retrieved from hospital discharge files,
clinical records, clinic visits, electronic medical records,
patients’ questionnaires, and ad hoc clinical databases.
Follow-up visits are scheduled according to the standard
practice of the site and as per the treating physician’s
best judgement.
The data are recorded on an electronic case report
form (eCRF) that is accessed via a secure web portal
hosted by Quintiles (a contract research organisation).
The eCRF has specific questions in English about the
manifestations of TSC and results of relevant investiga-
tions and treatment. Input of data is carried out by local
investigators or their deputies, and then independently
checked by a network of clinical research associates for
accuracy and consistency using the original local case
records. The web portal has an explanatory manual to
guide the investigators. Utmost care has been taken
during the design of the eCRF and the explanatory
manual to ensure that they are comprehensible to individ-
uals from different participating countries where English is
not the first language. Individual demographic data such as
name, address, hospital, and/or health insurance number
are not uploaded to the web portal so that anonymity can
be maintained.
TOSCA registry is not designed as a population-based
epidemiological registry; therefore, may not provide repre-
sentative incidence and prevalence data on the disease
and its manifestations.
The TOSCA Post-Authorization Safety Study (PASS) is
a drug safety sub-study which is based on a requirement
of the European Medicines Agency (EMA). The purpose
of TOSCA PASS is to obtain data to assess the long-term
safety and tolerability profile of everolimus (Votubia®) in
approved indications for the treatment of patients with
TSC residing in the European Union.
Eligibility criteria
Patients of any age diagnosed with TSC could participate
in the registry. Each patient must have a documented visit
for TSC within the preceding 12 months or must be newly
diagnosed with TSC prior to agreement to participate in
the registry. To be eligible for TOSCA PASS, participants
from TOSCA must be on everolimus (Votubia®) for an
approved TSC indication in the European Union. All
patients (parents or guardians, where applicable) must
sign the informed consent form before any information or
data is provided to the registry.
Study duration
The first patient was entered in the registry in August
2012. The initial enrolment period was of 24 months.
The patients will be followed up for up to 5 years. Forpaediatric patients included in TOSCA PASS, the
follow-up period will be extended until they reach Tanner
stage V if evaluated per local routine practice, or until the
age of 16 years for females and 17 years for males, regard-
less of whether the therapy has ended. This prolonged
follow-up period will ensure collection of long-term data
on safety and on the impact of the drug on sexual matur-
ation and potential fertility.
Objectives and main variables
The objectives of TOSCA include mapping the course of
TSC manifestations and their effects on prognosis by
obtaining information such as the proportion of patients
with each TSC manifestation (e.g., SEGA, renal angiomyo-
lipoma, LAM); the presence of any relationship between
manifestations affecting different organs and the time of
their appearance; prevalence of single organ manifesta-
tions and their natural history. The incidence and preva-
lence of rare symptoms (like pancreatic neuroendocrine
tumour, chordoma, perivascular epithelioid cell tumour,
hemi hypertrophy, secreting pituitary adenoma, hamar-
toma of the stomach, scoliosis, thickening and sclerosis of
the calvarium, parathyroid adenoma) and comorbidities
will also be obtained. Interventions and their outcomes
will be recorded with an aim of assessing their frequency
by type, by the order of their use and by the role of treat-
ing physician. The outcome of each manifestation will be
assessed by the type of intervention. Scientific hypotheses
to be tested in preclinical and/or clinical investigations will
be identified. Validated questionnaires will assess QOL of
patients with TSC. The objectives of the TOSCA registry
and TOSCA PASS sub-study with the main variables are
listed in Tables 1 and 2, respectively.
Statistical considerations
It was estimated that approximately 2000 patients meeting
eligibility criteria would be enrolled from about 250 sites
across 31 countries in TOSCA (Figure 3). TOSCA PASS
was expected to enrol at least 150 patients from about 100
sites across 15 countries. Formal sample size estimation
was not required due to the descriptive nature of this
registry, thus allowing flexibility in the number of patients
to be enrolled.
All patients enrolled in the TOSCA disease registry will
be considered in the analysis. Data will be summarised with
respect to the background (demography, genotype, family
history, age at diagnosis), clinical features (neurological,
neuropsychiatric, renal, cardiovascular, pulmonary, derma-
tological), rare manifestation, and co-morbidities of each
patient. Each variable will be analysed as a whole. Continu-
ous variables will be analysed in terms of value at the time
of registration and change from baseline at subsequent
examinations. Categorical variables (e.g., presence/absence
of a condition or manifestation) will be analysed in terms of
Table 1 TOSCA objectives and main variables
Objectives Main variables
To map the course of TSC manifestations
and their prognostic roles
Proportion of patients with each TSC manifestation
(e.g., SEGA, angiomyolipoma, lymphangioleiomyomatosis),
its complications and overall survival
To identify patients with rare symptoms
and comorbidities
Incidence and prevalence of rare symptoms and comorbidities
To record interventions and their outcomes Frequency of interventions by type, by sequence and by
role of the treating physician, and of physician specialty
and referral to site of excellence
Outcome of manifestations by type of intervention
Frequency and type of follow-up visits, imaging/tests,
hospitalisation, emergency room visits and surgical procedures
To contribute to creating an evidence base for
disease assessment and therapy and inform
research on TSC
Identification of scientific hypotheses to be tested in preclinical
and/or clinical investigations; promote observational and
experimental prospective studies on specific groups of patients
To measure quality of life in patients with TSC Validated questionnaires on quality of life
To collect information on sexual maturation/endocrine
assessments in patients with TSC, if available
Endocrine assessments (e.g., FSH, LH, Inhibin B, estradiol,
testosterone, progesterone)
Abbreviations: FSH follicle stimulating hormone, LH luteinising hormone, SEGA subependymal giant cell astrocytoma, TOSCA TuberOus SClerosis registry to increase
disease Awareness, TSC, tuberous sclerosis complex.
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follow-up. Missing data will not be imputed.
TOSCA registry organisation
TOSCA registry organisation (Figure 4) includes the
Scientific Advisory Board (SAB), a Working Committee,
and Research Groups, which work in collaboration.
Scientific advisory board
The Scientific Advisory Board consists of up to 30 mem-
bers (TSC healthcare professionals from various specialities
and patients’ association group representatives) external to
the sponsor and a maximum of three representatives of the
sponsor. The Scientific Advisory Board is responsible for
the scientific principles of the registry, promotion of the use
of the registry in the participating sites, publication of data
in agreement with the publication policy, and approval of
research projects. The chairperson, elected by the members
of the SAB, presides over and facilitates the running of SAB
meetings for a period of 12 months.Table 2 TOSCA PASS objectives and main variables
Objectives
To document the long-term safety and tolerability profile
of everolimus in the treatment of patients with TSC residing
in the European Union who are prescribed everolimus for
approved indications
To collect everolimus therapeutic drug monitoring data
within routine clinical practice as per the Summary of
Product Characteristics
Abbreviations: AE adverse event, PASS post-authorization safety study, SAE serious a
TSC tuberous sclerosis complex.Working committee
The Working Committee is a subgroup consisting of up
to 14 members from the SAB and is responsible for the
registry content and coordination of all the operational
activities. The Working Committee is also responsible
for defining the statistical analysis plan and publication
policy, and for developing and maintaining the database
structure of the registry in collaboration with other mem-
bers, according to their specialty and research interests.Research groups
Any participating centre can submit a specific research pro-
posal for inclusion into the TOSCA database. Letters of
intent are submitted annually to the working committee,
which recommends a set number of projects for potential
inclusion. Accepted ‘petal’ project participants form a
Research Group, which may consist of a variable number of
physicians participating in the registry. Each Research Group
is responsible for submission of a research project proposal
to the Working Committee, and for the management andMain variables
Incidence of AEs, SAEs, and everolimus-related
AEs in the observation period
Incidence of events of special interest (e.g., noninfectious
pneumonitis, severe infections, hypersensitivity, stomatitis,
secondary amenorrhea in post-adolescent females, etc.)
Everolimus blood concentration, if available
dverse event, TOSCA TuberOus SClerosis registry to increase disease Awareness,
Figure 3 Countries participating in TOSCA.
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Participation in Research Group projects is not mandatory
for all sites.
Publication policy
Results of the analyses will be submitted for publication
and/or posted in a publicly accessible database. Publica-
tions will be based on data from all sites that are analysed.
The Working Committee is responsible for developmentFigure 4 TOSCA registry organisation.and coordination of publications and for ensuring that
planned timelines are met. The Working Committee also
coordinates reviews and approvals.
Ethical compliance
Written informed consents were obtained from all pa-
tients, parents, or guardians to participate in TOSCA and
TOSCA PASS. The protocol was approved by an ethics
committee at each centre, before the first patient was en-
rolled. This study has been designed and is being imple-
mented and reported in accordance with the Guidelines
for Good Pharmacoepidemiology Practices (GPP) of the
International Society for Pharmacoepidemiology (ISPE),
the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) guidelines, and the ethical
principles laid down in the Declaration of Helsinki.
Results
Administrative analysis
The first administrative analysis was performed in
March 2013 on complete data collected for baseline
‘core’ data set for the first 100 patients with the aim of
evaluating feasibility and accuracy of the data collection
procedure. A total of 469 fields of information were
evaluated for each of the 100 patients. In more than 90%
of patients, information on 85% of the fields was found
to be complete. The administrative analysis showed a
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collected data. Subsequent interim analyses are planned
approximately every 12 months starting from 2014.
These interim analyses aim to review, analyse, and
publish the findings.Current enrolment
Although enrolment was closed on 10 August 2014, the
registry continues to recruit patients who are eligible for
TOSCA PASS sub-study. This recruitment is being done
to have at least 150 patients in TOSCA PASS, as per the
commitment made to EMA. As of 24 September 2014, a
total of 2216 patients had been enrolled in TOSCA, of
which, 162 patients are also eligible for TOSCA PASS
sub-study.Discussion
The complexity of the disease due to multisystem involve-
ment and the difficulty in finding sufficient cases due to
rarity of the disease make systematic study of TSC a real
challenge. Pragmatic clinical studies have been conducted
in patients with TSC but typically based on smaller sample
sizes [17,24-27,32,33]. Good understanding of the natural
course of the disease, which requires examining a large
sample over an extended period of time, is essential to
develop appropriate management strategies.
While randomised controlled trials form an important
part of research and are considered the gold standard to
evaluate treatment efficacy, patient registries also play an
important role in describing the natural course of the dis-
ease and thus in identifying optimal disease management
strategies [37]. Patient registries are helpful tools to address
questions or issues that may not be addressed in clinical
trials, including description of patients that cannot be in-
cluded in trials. In fact, randomised controlled trials and
patient registries complement each other in the evaluation
of patient outcomes [37]. Patient registries are very good
tools to study characteristics of a disease, its management,
and outcomes with or without treatment. Registries help in
improving patient care and healthcare planning especially
for rare diseases and also contribute to improving social,
economic, and QOL outcomes in these diseases [38].
Registries established for rare genetic diseases have
helped the participants to meet others with similar con-
ditions and also benefited the researches to gain access
to huge amount of relevant information. The European
Huntington’s Disease Network that was established in 2004
enrolled a large number of patients from 13 European
countries, thereby demonstrating the feasibility to collect
data across countries speaking different languages [39].
Also notable are TREAT-NMD (Translational Research in
Europe -Assessment and Treatment of Neuromuscular
Diseases) Duchenne muscular dystrophy registries,which are standardised registries for patients with Duchenne
muscular dystrophy from several countries [40].Significance of TOSCA
This international multicentre registry has been designed
to study a large cohort of patients with TSC from different
ethnic groups over a prolonged period of time, to obtain
answers to some specific questions, and to fill some of the
existing gaps. TOSCA will investigate outcomes of inter-
ventions under natural conditions. As the data will be
obtained from a large patient population, the analysis will
have more power. Collaboration of an academic steering
committee, a pharmaceutical company, and patient/carer
organisations is a major strength of TOSCA. The registry
includes a subsection/petal completely dedicated to the
wider needs of the patients. Various TSC patient commu-
nities have been involved in this ‘petal’. This subsection
will help to evaluate the impact of the disease on the life
of families of the affected individuals. Similarly, each of
the other petals will add to the existing knowledge in the
respective areas.How does TOSCA aim to address the gaps?
The TOSCA database has been designed to provide both
cross-sectional and longitudinal data on TSC. General
information collected in the ‘core’ section of the registry
from a large patient population worldwide will help in
identifying trends. TOSCA will help to obtain data on
various diagnostic and treatment strategies and study
the impact of the same. We will understand whether the
time and the method of diagnosis of TSC and its mani-
festations differ in various countries. We will know
whether the methods for the various interventions in-
cluding the order in which they are administered in dif-
ferent countries are similar. The data obtained can also
help to understand whether rare manifestations are truly
rare and whether certain co-morbidities are more fre-
quent than others. Information on current use of genetic
tests for diagnosis in different countries and information
on affected family members (mother/father, number of
relatives affected) will also be obtained. In addition, we
will acquire information on patient needs and QOL.
Specific ‘subsections’ designed as research projects will
collect more detailed information. Each research project
has a main question that essentially is a gap in the under-
standing of the disease. Information from the ‘core’ section
along with the additional questions will help to fill the
gap. Research projects related to SEGA, renal angiomyoli-
poma, genetics, epilepsy, TSC-associated neuropsychiatric
disorders, and patient socioeconomics questionnaires will
be launched in 2014. Additional research projects (related
to, skin/eye manifestations and LAM) will be analysed and
may be launched at a later date.
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Overall safety data for everolimus in TSC available from
completed, controlled and uncontrolled studies indicate
that everolimus is generally well tolerated. The safety
profile is characterised by manageable adverse events
that are generally reversible and non-cumulative [24-27].
TOSCA PASS will provide additional safety data for
everolimus when used for prolonged periods in a larger
number of patients, similar to phase IV studies.Overcoming challenges
Some of the challenges in conducting patient registries are
ensuring continuous data entry, data quality, and complete-
ness. It is important to assess the feasibility of the registry
and to ensure efficiency of the data collection procedure
[41]. The results of the first administrative analysis con-
ducted for this purpose have been encouraging. The ‘core’
section was purposely designed as the mandatory section to
improve completeness of the data entered in the registry.
Annual data collection was selected to ensure longitudinal
progression, whilst not being too cumbersome.
It is important to be mindful that TOSCA is not a
population-based study. Patients are enrolled from hospital
services and specialised centres and may not represent all
cases of TSC. While more severe cases are likely to be
over-represented, there is a probability of missing less
severe cases that are undiagnosed or do not require medical
care. To reduce this bias, TOSCA investigators are encour-
aged to seek consent for participation from all patients
meeting the eligibility criteria.
Future studies must aim to cover the entire population.Conclusion
The results from this registry will provide better under-
standing of the natural history of the disease and will
facilitate development of better management and sur-
veillance strategies for patients with TSC. The informa-
tion collected from this large cohort of patients with
TSC will guide future research. This is a model study
that could promote observational and experimental
prospective studies on specific groups of patients in
other rare diseases.Abbreviations
AE: Adverse event; EMA: European Medicines Agency; FSH: Follicle
stimulating hormone; GPP: Good pharmacoepidemiology practices;
ISPE: International Society for Pharmacoepidemiology;
LAM: Lymphangioleiomyomatosis; LH: Luteinising hormone;
mTOR: Mammalian target of rapamycin; PASS: Post-Authorization Safety
Study; QOL: Quality of life; SAB: Scientific Advisory Board; SAE: Serious
adverse event; SEGA: Subependymal giant cell astrocytoma;
STROBE: Strengthening the reporting of observational studies in
epidemiology; TAND: TSC-associated neuropsychiatric disorders;
TOSCA: TuberOus SClerosis registry to increase disease Awareness;
TSC: Tuberous sclerosis complex.Competing interests
RC, S Crippa, S Comis and BU are employees of Novartis. All authors are
members of TOSCA Scientific Advisory Board and have received honorarium
from Novartis. JCK and BZ report receiving grants from Novartis. ACJ, SJ, and
VC received lecture fees from Novartis. MS has received personal fees for
consultancy activities and lectures and financial support for investigator
driven research from Novartis. PJdV has been a co-principal investigator on
research studies funded by Novartis.
Authors’ contributions
All authors contributed in the conception and design of the registry; helped
to draft and revise the manuscript; and read and approved the final
manuscript.
Acknowledgements
We thank patients and their families, investigators, and staff from all the
participating sites. We thank Gabriella Gislimberti, clinical trial manager,
Novartis Farma SpA. We thank Kshama Chitnis, Novartis Healthcare Pvt. Ltd.
for providing medical editorial assistance with this manuscript.
Funding
This study is funded by Novartis Pharma AG.
Author details
1Sussex Kidney Unit, Royal Sussex County Hospital, Eastern Road, Brighton
BN2 5BE, UK. 2IRCCS AUO San Martino IST–Istituto Nazionale per la Ricerca
sul Cancro, Genoa, Italy. 3Tor Vergata University Hospital, Rome, Italy.
4Division of Child and Adolescent Psychiatry, University of Cape Town, Cape
Town, South Africa. 5Associazione Sclerosi Tuberosa ONLUS, Milan, Italy.
6European Tuberous Sclerosis Complex Association, In den Birken, 30, 45711
Dattein, Germany. 7Vivantes-Klinikum Neukölln, Berlin, Germany. 8UZ Brussel
VUB, Brussels, Belgium. 9The Children’s Memorial Health Institute of Warsaw,
Warsaw, Poland. 10Hospital Necker Enfants Malades, Paris, France.
11Medizinische Klinik und Poliklinik IV, Klinikum der Universität München,
Munich, Germany. 12Hôpital Nord, Saint Etienne, France. 13Institute of Child
Health, University College London, London, UK. 14University Medical Center,
Utrecht, Netherlands. 15Novartis Farma S.p.A., Origgio, Italy. 16Association
Sclérose Tubéreuse de Bourneville, Gradignan, France. 17Moscow Institute of
Pediatrics and Pediatric Surgery, Moscow, Russian Federation. 18TSA Tuberous
Sclerosis Association, Nottingham, UK. 19Hôpital Louis Pradel, Claude Bernard
University Lyon 1, Lyon, France. 20Karolinska University Hospital, Stockholm,
Sweden. 21Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal. 22Hospital
Universitari Vall d’Hebron, Barcelona, Spain. 23SPS Pediatrična Klinika,
Ljubljana, Slovenia. 24Tallinn Children Hospital, Tallinn, Estonia. 25“St. Sophia”
Children’s Hospital, Athens, Greece. 26Novartis Pharma AG, Basel, Switzerland.
27Universitätsklinik für Kinder-und Jugendheilkunde, Vienna, Austria.
Received: 25 July 2014 Accepted: 4 November 2014
References
1. Curatolo P, Bombardieri R, Jozwiak S: Tuberous sclerosis. Lancet 2008,
372:657–668.
2. Sampson JR, Scahill SJ, Stephenson JB, Mann L, Connor JM: Genetic aspects
of tuberous sclerosis in the west of Scotland. J Med Genet 1989, 26:28–31.
3. O’Callaghan FJ, Shiell AW, Osborne JP, Martyn CN: Prevalence of tuberous
sclerosis estimated by capture-recapture analysis. Lancet 1998, 351:1490.
4. Yates JR: Tuberous sclerosis. Eur J Hum Genet 2006, 14:1065–1073.
5. Curatolo P, Maria BL: Tuberous sclerosis. Handb Clin Neurol 2013, 111:323–331.
6. Józwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J: Usefulness of
diagnostic criteria of tuberous sclerosis complex in pediatric patients.
J Child Neurol 2000, 15:652–659.
7. Franz DN, Bissler JJ, McCormack FX: Tuberous sclerosis complex:
neurological, renal and pulmonary manifestations. Neuropediatrics 2010,
41:199–208.
8. Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA: The natural
history of epilepsy in tuberous sclerosis complex. Epilepsia 2010,
51:1236e41.
9. Prather P, de Vries PJ: Behavioral and cognitive aspects of tuberous
sclerosis complex. J Child Neurol 2004, 19:666–674.
Kingswood et al. Orphanet Journal of Rare Diseases 2014, 9:182 Page 9 of 9
http://www.ojrd.com/content/9/1/18210. Crino P, Mehta R, Vinters H: Pathogenesis of TSC in the Brain. In Tuberous
Sclerosis Complex: Genes, Clinical Features, and Therapeutics. Edited by Kwiatkowsi
D, Whittemore V, Thiele E. Weinheim: Wiley-Blackwell; 2010:285–309.
11. Goh S, Butler W, Thiele EA: Subependymal giant cell tumors in tuberous
sclerosis complex. Neurology 2004, 63:1457–1461.
12. Shepherd CW, Gomez MR, Lie JT, Crowson CS: Causes of death in patients
with tuberous sclerosis. Mayo Clin Proc 1991, 66:792–796.
13. Mavroudi M, Zarogoulidis P, Katsikogiannis N, Tsakiridis K, Huang H, Sakkas A,
Kallianos A, Rapti A, Sarika E, Karapantzos I, Zarogoulidis K:
Lymphangioleiomyomatosis: current and future. J Thorac Dis 2013, 5:74–79.
14. Cudzilo CJ, Szczesniak RD, Brody AS, Rattan MS, Krueger DA, Bissler JJ, Franz
DN, McCormack FX, Young LR: Lymphangioleiomyomatosis screening in
women with tuberous sclerosis. Chest 2013, 144:578–585.
15. Seibert D, Hong CH, Takeuchi F, Olsen C, Hathaway O, Moss J, Darling TN:
Recognition of tuberous sclerosis in adult women: delayed presentation
with life-threatening consequences. Ann Intern Med 2011, 154:806–813.
16. Crino P, Nathanson K, Henske E: The tuberous sclerosis complex. New Engl
J Med 2006, 355:1345–1356.
17. Jóźwiak S, Kotulska K, Kasprzyk-Obara J, Domańska-Pakieła D, Tomyn-Drabik M,
Roberts P, Kwiatkowski D: Clinical and genotype studies of cardiac
tumors in 154 patients with tuberous sclerosis complex. Pediatrics 2006, 118:
e1146–e1151.
18. Roach ES, Smith M, Huttenlocher P, Bhat M, Alcorn D, Hawley L: Report of
the diagnostic criteria committee of the National Tuberous Sclerosis
Association. J Child Neurol 1992, 7:221–224.
19. Roach E, Gomez M, Northrup H: Tuberous sclerosis complex consensus
conference: revised clinical diagnostic criteria. J Child Neurol 1998,
13:624–628.
20. Roach ES: Are diagnostic criteria for tuberous sclerosis still relevant?
Pediatr Neurol 2013, 49:223–224.
21. Northrup H, Krueger DA, International Tuberous Sclerosis Complex
Consensus Group: Tuberous sclerosis complex diagnostic criteria update:
recommendations of the 2012 international tuberous sclerosis complex
consensus conference. Pediatr Neurol 2013, 49:243–254.
22. Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus
Group: Tuberous sclerosis complex surveillance and management:
recommendations of the 2012 International Tuberous Sclerosis Complex
Consensus Conference. Pediatr Neurol 2013, 49:255–265.
23. Huang J, Manning BD: The TSC1-TSC2 complex: a molecular switchboard
controlling cell growth. Biochem J 2008, 412:179–190.
24. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson
KA, Byars A, Sahmoud T, Franz DN: Everolimus for subependymal giant-
cell astrocytomas in tuberous sclerosis. N Engl J Med 2010, 363:1801–1811.
25. Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN: Everolimus
long-term safety and efficacy in subependymal giant cell astrocytoma.
Neurology 2013, 80:574–580.
26. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O,
Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele
EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S: Efficacy and
safety of everolimus for subependymal giant cell astrocytomas associated
with tuberous sclerosis complex (EXIST-1): a multicentre, randomised,
placebo-controlled phase 3 trial. Lancet 2013, 381:125–132.
27. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova
E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen
D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K: Everolimus for
angiomyolipoma associated with tuberous sclerosis complex or sporadic
lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised,
double-blind, placebo-controlled trial. Lancet 2013, 381:817–824.
28. Afinitor (Everolimus) Tablets for Oral Administration Prescribing Information.
New Jersey, NJ: Novartis Pharmaceuticals Corporation; 2014 [https://www.
pharma.us.novartis.com/product/pi/pdf/afinitor.pdf]
29. Votubia (Everolimus) Summary of Product Characteristics. West Sussex, UK:
Novartis Europharm Limited; 2014 [http://www.votubia.com/pdf/Votubia-SMPC
%20Oct%202014.pdf].
30. Curatolo P, Moavero R: mTOR inhibitors in tuberous sclerosis complex.
Curr Neuropharmacol 2012, 10:404–415.
31. Kohrman MH: Emerging treatments in the management of tuberous
sclerosis complex. Pediatr Neurol 2012, 46:267–275.
32. Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C,
Mays M, Lopez CM, Kim MO, Franz DN: Everolimus treatment of refractory
epilepsy in tuberous sclerosis complex. Ann Neurol 2013, 74:679–687.33. Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL,
Watson PC, Howe CJ, Doyle T, Pointon K, Cross JJ, Tattersfield AE,
Kingswood JC, Sampson JR: Sirolimus therapy for angiomyolipoma in
tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2
trial. Clin Cancer Res 2011, 17:4070–4081.
34. Cappellano AM, Senerchia AA, Adolfo F, Paiva PM, Pinho R, Covic A, Cavalheiro
S, Saba N: Successful everolimus therapy for SEGA in pediatric patients with
tuberous sclerosis complex. Childs Nerv Syst 2013, 29:2301–2305.
35. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF,
Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ,
Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen
MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC, National
Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group:
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J
Med 2011, 364:1595–1606.
36. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS,
Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D,
Kwiatkowski DJ: Mutational analysis in a cohort of 224 tuberous sclerosis
patients indicates increased severity of TSC2, compared with TSC1,
disease in multiple organs. Am J Hum Genet 2001, 68:64–80.
37. Dreyer NA, Garner S: Registries for robust evidence. JAMA 2009, 302:790–791.
38. Gliklich RE, Dreyer NA: Patient Registries. In Registries for Evaluating Patient
Outcomes: A User’s Guide. 2nd edition. Edited by Gliklich RE, Dreyer NA.
Rockville: Agency for Healthcare Research and Quality (US); 2010:9–21.
39. Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E,
Tabrizi SJ, Landwehrmeyer GB, the European Huntington’s Disease
Network: Observing huntington’s disease: the European Huntington’s
Disease Network’s REGISTRY. PLoS Curr Huntington Dis 2010, (1st Edition):
doi:10.1371/currents.RRN1184.
40. Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H, Roy A,
Chamova T, Guergueltcheva V, Korngut L, Campbell C, Dai Y, Barišić N, Kos
T, Brabec P, Rahbek J, Lahdetie J, Tuffery-Giraud S, Claustres M, Leturcq F,
Ben Yaou R, Walter MC, Schreiber O, Karcagi V, Herczegfalvi A, Viswanathan
V, Bayat F, de la Caridad Guerrero Sarmiento I, Ambrosini A, Ceradini F, et al:
The TREAT-NMD Duchenne muscular dystrophy registries: conception,
design, and utilization by industry and academia. Hum Mutat 2013,
34:1449–1457.
41. Gliklich RE, Dreyer NA: Data Collection and Quality Assurance. In Registries
for Evaluating Patient Outcomes: A User’s Guide. 2nd edition. Edited by
Gliklich RE, Dreyer NA. Rockville: Agency for Healthcare Research and
Quality (US); 2010:225–252.
doi:10.1186/s13023-014-0182-9
Cite this article as: Kingswood et al.: TOSCA – first international registry
to address knowledge gaps in the natural history and management of
tuberous sclerosis complex. Orphanet Journal of Rare Diseases 2014 9:182.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
